Literature DB >> 19996214

Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.

Valentina Monica1, Giorgio V Scagliotti, Paolo Ceppi, Luisella Righi, Alberto Cambieri, Marco Lo Iacono, Silvia Saviozzi, Marco Volante, Silvia Novello, Mauro Papotti.   

Abstract

PURPOSE: In non-small cell lung cancer, higher thymidylate synthase (TS) levels have been reported in squamous cell carcinoma (SCC) compared with adenocarcinoma (ADC). Data on TS expression in large-cell carcinoma (LCC) are scanty. EXPERIMENTAL
DESIGN: TS mRNA and protein levels were analyzed in 42 surgical cases of pulmonary LCC, including 8 large-cell neuroendocrine carcinomas, and were compared with controls represented by ADC (n = 41), SCC (n = 30), and small-cell lung carcinoma (SCLC; n = 33). TS levels were also correlated with the expression of Ki67 and E2F1. Moreover, the reliability of TS expression analysis was assessed in 22 matched cytologic and surgical specimens of non-small cell lung cancer.
RESULTS: TS mRNA levels of LCC were comparable with those of control SCC, but significantly higher than those of ADC (P < 0.001) and lower than SCLC (P < 0.001). A correlation between TS mRNA and protein levels was observed in control ADC and SCC, but not in LCC. Large-cell neuroendocrine carcinomas had the highest TS expression, whereas in non-neuroendocrine LCCs, TS protein levels were significantly higher (P = 0.02) in LCC immunoreactive for p63 and desmocollin3 (markers of squamous differentiation) than those expressing TTF-1 (a marker of ADC). Both E2F1 and Ki67 levels were not correlated with TS in LCCs. Finally, a linear correlation in TS protein levels was observed between matched cytologic and surgical specimens.
CONCLUSION: The pulmonary LCC immunoprofile may resemble that of SCCs or ADCs. This immunoprofile is associated with differential TS expression levels, which may support a more appropriate therapeutic strategy decision. (Clin Cancer Res 2009;15(24):7547-52).

Entities:  

Year:  2009        PMID: 19996214     DOI: 10.1158/1078-0432.CCR-09-1641

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 2.  Chemotherapy advances in small-cell lung cancer.

Authors:  Bryan A Chan; Jermaine I G Coward
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

3.  Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.

Authors:  Ming-Lei Zhuo; Hua Bai; Zhi-Jie Wang; Jian-Chun Duan; Tong-Tong An; Mei-Na Wu; Jun Zhao; Yu-Yan Wang; Shu-Hang Wang; Jie Wang
Journal:  Mol Clin Oncol       Date:  2014-07-24

Review 4.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

5.  Customizing systemic therapy in patients with advanced non-small cell lung cancer.

Authors:  A M Sadowska; V Nowé; A Janssens; E Boeykens; W A De Backer; P R Germonpré
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

6.  Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Authors:  Daniel C Christoph; Bernadette Reyna Asuncion; Biftu Hassan; Cindy Tran; Julia D Maltzman; Daniel J O'Shannessy; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Mathias Hoiczyk; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

7.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

Authors:  K Takezawa; I Okamoto; S Tsukioka; J Uchida; M Kiniwa; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

8.  Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

Authors:  A T Shaw; A M Varghese; B J Solomon; D B Costa; S Novello; M Mino-Kenudson; M M Awad; J A Engelman; G J Riely; V Monica; B Y Yeap; G V Scagliotti
Journal:  Ann Oncol       Date:  2012-08-10       Impact factor: 32.976

9.  Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.

Authors:  G Rossi; M C Mengoli; A Cavazza; D Nicoli; M Barbareschi; C Cantaloni; M Papotti; A Tironi; P Graziano; M Paci; A Stefani; M Migaldi; G Sartori; G Pelosi
Journal:  Virchows Arch       Date:  2013-11-13       Impact factor: 4.064

10.  Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.

Authors:  Natasha Rekhtman; Laura J Tafe; Jamie E Chaft; Lu Wang; Maria E Arcila; Agnes Colanta; Andre L Moreira; Maureen F Zakowski; William D Travis; Camelia S Sima; Mark G Kris; Marc Ladanyi
Journal:  Mod Pathol       Date:  2012-11-30       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.